U.S. health authorities are supporting a more accessible approach to cervical cancer prevention, a method with limited availability in Canada. The Health Resources and Services Administration recently released new guidelines that will eventually make it easier for women and individuals assigned female at birth to obtain at-home self-testing kits for the human papillomavirus (HPV), a sexually transmitted infection that can lead to cervical cancer. This shift signifies a move away from the conventional Pap test in favor of HPV tests, which can be conducted by either a healthcare provider or an individual.
Early detection of cervical cancer through regular screening can result in a 90 percent five-year survival rate. While many Canadian jurisdictions now advocate for HPV screening over the traditional Pap test to prevent cervical cancer, self-administered tests are not widely accessible outside of British Columbia.
The at-home HPV testing kits function similarly to rapid COVID-19 tests conducted at home. They involve using a swab to collect a specimen from the vagina, without the need for a speculum like in a Pap test or clinician-administered HPV test. The swab does not need to touch or scrape the cervix, reducing discomfort often associated with Pap tests.
Unlike rapid COVID-19 tests, HPV screening samples must be sent to a lab for testing, not providing instant results. Self-collection not only allows for convenient testing at home but also encourages more individuals to undergo HPV screening, including those who have never been tested or do not get tested regularly, according to the Canadian Partnership Against Cancer.
Pap smears detect abnormal or precancerous cells in the cervix and have an accuracy rate of less than 60 percent, as reported in a 2022 study by the Canadian Medical Association Journal. On the other hand, HPV testing focuses on detecting the DNA of the virus rather than examining the patient’s cells, boasting an accuracy rate of over 90 percent in virus detection, as per the study findings.
Nearly all cervical cancer cases are linked to HPV, with specific strains responsible for more than 70 percent of cases worldwide. A positive HPV test does not guarantee cancer development but may necessitate further examination, potentially including a Pap test. However, there are rare cases where HPV testing may not aid in detection.
Health Canada currently recommends Pap tests every three years and HPV screening every five years. The latest U.S. recommendations allow individuals between 30 and 65 years of age, with an average risk of cervical cancer, the option to self-test. Starting January 1, 2027, most private insurance companies will cover the cost of these tests. Individuals can still choose to have a healthcare provider conduct an HPV test or Pap smear.
The American Cancer Society estimates around 13,000 new cervical cancer cases are diagnosed annually in the U.S., resulting in about 4,300 deaths each year. HPV infections are common, with 75 percent of sexually active individuals experiencing at least one HPV infection in their lifetime, often without symptoms. Vaccination against carcinogenic and non-cancer causing HPV strains has contributed to a decline in cases, although recent data suggests a plateau in progress.
Cervical cancer rates in Canada declined steadily from 1984 to 2005 but have plateaued since then, according to the Canadian Cancer Statistics Advisory Committee. Although cervical cancer is not a leading cause of cancer-related deaths in Canada, the report highlighted that each of the 430 expected deaths in 2025 due to cervical cancer could have been preventable.
British Columbia initiated a cervical cancer self-screening program in January 2024, with other provinces like Prince Edward Island, Alberta, Manitoba, and Newfoundland and Labrador conducting self-screening pilot projects. Ontario offers HPV self-testing, but it is not covered under the provincial insurance program. Private companies in some regions offer the kits for purchase.